PCNSL
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
UNION therapeuticsDenmark - Hellerup
1 program1
Pirtobrutinib, Sintilimab, Rituximab, MethotrexatePhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
UNION therapeuticsPirtobrutinib, Sintilimab, Rituximab, Methotrexate
InnoCareICP-022
Clinical Trials (2)
Total enrollment: 171 patients across 2 trials
A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)
Start: Dec 2025Est. completion: Jun 2029110 patients
Phase 2Recruiting
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
Start: Jun 2019Est. completion: Dec 202361 patients
Phase 2Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 171 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.